Elena Beketova
Targeting PRMT5 as a novel approach for the treatment of castration-resistant prostate cancer
Contact Info:Training Group(s):
Current Research Interests:
Our lab studies mechanisms of prostate cancer therapy resistance. My research aims to identify targetable pathways regulating expression of androgen receptor because androgen receptor signaling is a major driving force of prostate cancer progression. Recently our group demonstrated that protein arginine methyltransferase 5 (PRMT5), an emerging oncogene in various cancers that symmetrically dimethylates arginine residues of histone and non-histone substrates, regulates hormone-naïve prostate cancer (HNPC) cell growth in AR-dependent manner. I am currently expanding these findings to castration resistant prostate cancer.- Student Profile
